|
Press Release
|
|
Written by Datamonitor
|
|
Friday, 29 May 2009 |
APA meeting 2009: new schizophrenia products and depot formulations
The annual meeting of the American Psychiatric Association is the year's largest psychiatry event. This year's conference in San Francisco indicated that long-acting depot versions of atypical antipsychotics continue to prove useful tools in the treatment of schizophrenia. In addition, new potential market entrants reported mixed data from new oral antipsychotics.
|
|
Read more...
|
|
|
Business for Sale
|
|
Written by Martina Ivanisevic
|
|
Friday, 29 May 2009 |
API Manufacturer from India - Looking for Strategic Investor
Company was estabilished in the year 2004 by a group of technocrats from renowned Dr.Reddys Laboratories Limited. All the key personnel have expertise in their respective areas of specialization. Strong R&D, Analytical capabilities, versatile human resources and well vision management are the core competencies of the company.
Today the Group is operating with one Intermediate manufacturing unit and one API manufacturing unit both are located in Pashamylaram IDA, 25 KMs away from Hyderabad.
|
|
Read more...
|
|
|
Press Release
|
|
Written by Datamonitor
|
|
Friday, 22 May 2009 |
GCC healthcare: in pursuit of western standards
The healthcare sector in the Gulf Cooperation Council countries is currently undergoing a wave of reforms intended to achieve and sustain international standards of healthcare delivery. Datamonitor believes that the region has the potential to achieve these aims if it reforms healthcare insurance, develops a workforce of healthcare professionals, and accepts the use of generic pharmaceuticals.
|
|
Read more...
|
|
|
Business for Sale
|
|
Written by Martina Ivanisevic
|
|
Tuesday, 19 May 2009 |
Turkey - Pharmaceutical Company for Sale
Outside the BRIC (Brazil, Russia, India, China) states, Turkey is considered one of the key growth pharmaceutical markets globally. Growth has been rapid in recent years, with per capita spending reaching US$159 in 2008, a similar level to other emerging countries in Eastern Europe. The country's large, ageing and increasingly urbanised population, means both demand and access to medicines should increase in the future. Over the next five years, sales of pharmaceuticals, which include prescription drugs and over-the-counter (OTC) medicines, will increase from US$11.3bn to US$19.5bn, representing a compound annual growth rate (CAGR) of 11.6%.
|
|
Read more...
|
|
|
Press Release
|
|
Written by Datamonitor
|
|
Friday, 15 May 2009 |
Pandemic flu: gaps in preparedness remain
The current outbreak of influenza A (H1N1) is testing pandemic preparedness strategies across the globe. While widely implemented strategies seem to have prepared the world better than ever before, important gaps regarding the logistics of drug and vaccine distribution remain.
|
|
Read more...
|
|
|
Press Release
|
|
Written by Datamonitor
|
|
Friday, 08 May 2009 |
Antiviral sales boosted as UAE prepares for influenza A (H1N1)
The recent outbreak of influenza A (H1N1) infection, previously referred to as swine flu, has thrown the spotlight on governments around the world and their ability to manage a pandemic. In the UAE, customers are currently finding it difficult to source antivirals but, with Dubai seen as a hub for international travel, the government has stockpiles ready for distribution should an outbreak occur.
|
|
Read more...
|
|
|
Press Release
|
|
Written by Datamonitor
|
|
Tuesday, 05 May 2009 |
UK budget heralds price cuts on branded pharmaceuticals
As part of the UK government's drive to save GBP2.3 billion in the NHS during 2010-11, GBP550m will be cut from the prices of branded drugs as a result of the revised Pharmaceutical Price Regulation Scheme. With the volume of branded drugs having remained flat over the last four years, total sales of the UK branded pharmaceutical industry are forecast to decline from 2009 onwards.
|
|
Read more...
|
|
|
Open Innovation
|
|
Written by PricewaterhouseCoopers
|
|
Sunday, 26 April 2009 |
 Pharmaceutical companies will use virtual R&D to increase innovation and reduce commercial deficit
By 2020 the Pharma R&D process may be shortened by two-thirds,
success rates may dramatically increase, and clinical trial costs could
be cut substantially, according to research launched today by
PricewaterhouseCoopers, entitled Pharma 2020: Virtual R&D, which path will you take? New
computer based technologies will create a greater understanding of the
biology of disease and the evolution of ‘Virtual man’ to enable
researchers to predict the effects of new drug candidates before they
enter human beings. Along with changes underway in the regulatory and
socio-political environment, this will enable Pharma to overcome one of
the most fundamental issues it needs to resolve over the next decade.
|
|
Read more...
|
|
|
Press Release
|
|
Written by Datamonitor
|
|
Friday, 24 April 2009 |
GSK and Pfizer see strength in joint venture
GSK and Pfizer have agreed to merge their respective HIV businesses, creating a single specialist entity with total pro-forma sales of approximately $3 billion in 2008. Although a defensive move, the combination of marketing and distribution resources and the potential to create new lifecycle management strategies significantly improves the commercial outlook for each franchise.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 37 - 45 of 96 |
Farmavita.Net Journal 
